Myrthe J. VAN DIJK Follow-up results of a phase 2 study assessing the safety and efficacy of mitapivat treatment, an oral pyruvate kinase activator, for up to 60 weeks in subjects with sickle cell disease Thursday, June 16th 19:38 - 19:41 UTC+2 View all speakers
